CRISPR-Cas9-based target validation for p53-reactivating model compounds

Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9–based ta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Chem Biol
Autori principali: Wanzel, Michael, Vischedyk, Jonas B, Gittler, Miriam P, Gremke, Niklas, Seiz, Julia R, Hefter, Mirjam, Noack, Magdalena, Savai, Rajkumar, Mernberger, Marco, Charles, Joël P, Schneikert, Jean, Bretz, Anne Catherine, Nist, Andrea, Stiewe, Thorsten
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910870/
https://ncbi.nlm.nih.gov/pubmed/26595461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nchembio.1965
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi